These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36794629)

  • 1. The economic evaluation of ALS care: quality and cost.
    Çoban M; Bilge U; Balseven H; Uysal H; Artut B
    Amyotroph Lateral Scler Frontotemporal Degener; 2023 Aug; 24(5-6):502-513. PubMed ID: 36794629
    [No Abstract]   [Full Text] [Related]  

  • 2. Health and social care costs of managing amyotrophic lateral sclerosis (ALS): an Irish perspective.
    Connolly S; Heslin C; Mays I; Corr B; Normand C; Hardiman O
    Amyotroph Lateral Scler Frontotemporal Degener; 2015 Mar; 16(1-2):58-62. PubMed ID: 25285902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economic impact of amyotrophic lateral sclerosis: a systematic review.
    Gladman M; Zinman L
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):439-50. PubMed ID: 25924979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of illness in amyotrophic lateral sclerosis (ALS): a cross-sectional survey in Germany.
    Schönfelder E; Osmanovic A; Müschen LH; Petri S; Schreiber-Katz O
    Orphanet J Rare Dis; 2020 Jun; 15(1):149. PubMed ID: 32532288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of treatments for amyotrophic lateral sclerosis: a review of the literature.
    Ginsberg G; Lowe S
    Pharmacoeconomics; 2002; 20(6):367-87. PubMed ID: 12052096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the application of the European guidelines for the diagnosis and clinical care of amyotrophic lateral sclerosis (ALS) patients in six French ALS centres.
    Marin B; Beghi E; Vial C; Bernard E; Lautrette G; Clavelou P; Guy N; Lemasson G; Debruxelles S; Cintas P; Antoine JC; Camdessanche JP; Logroscino G; Preux PM; Couratier P;
    Eur J Neurol; 2016 Apr; 23(4):787-95. PubMed ID: 26833536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Cost-Effectiveness Framework for Amyotrophic Lateral Sclerosis, Applied to Riluzole.
    Thakore NJ; Pioro EP; Udeh BL; Lapin BR; Katzan IL
    Value Health; 2020 Dec; 23(12):1543-1551. PubMed ID: 33248509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The costs of amyotrophic lateral sclerosis, according to type of care.
    van der Steen I; van den Berg JP; Buskens E; Lindeman E; van den Berg LH
    Amyotroph Lateral Scler; 2009 Feb; 10(1):27-34. PubMed ID: 18608087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALS managed care considerations.
    Santaniello B
    Am J Manag Care; 2018 Aug; 24(15 Suppl):S336-S341. PubMed ID: 30207672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The economic burden of amyotrophic lateral sclerosis: a systematic review.
    Achtert K; Kerkemeyer L
    Eur J Health Econ; 2021 Nov; 22(8):1151-1166. PubMed ID: 34143346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Socioeconomic costs of amyotrophic lateral sclerosis according to staging system.
    Oh J; An JW; Oh SI; Oh KW; Kim JA; Lee JS; Kim SH
    Amyotroph Lateral Scler Frontotemporal Degener; 2015 Jun; 16(3-4):202-8. PubMed ID: 25646865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Over-, under- and misuse of pain treatment in Germany.
    Dietl M; Korczak D
    GMS Health Technol Assess; 2011 Apr; 7():Doc03. PubMed ID: 21522485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS).
    Fournier CN; Bedlack R; Quinn C; Russell J; Beckwith D; Kaminski KH; Tyor W; Hertzberg V; James V; Polak M; Glass JD
    JAMA Neurol; 2020 Apr; 77(4):480-488. PubMed ID: 31886839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical review and quality-assessment of cost analyses in radiotherapy: How reliable are the data?
    Defourny N; Monten C; Grau C; Lievens Y; Perrier L
    Radiother Oncol; 2019 Dec; 141():14-26. PubMed ID: 31630866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of the Content and Consistency of Methodological Quality and Transferability Checklists for Reviewing Model-Based Economic Evaluations.
    Lim KK; Koleva-Kolarova R; Fox-Rushby J
    Pharmacoeconomics; 2022 Oct; 40(10):989-1003. PubMed ID: 35907179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical cost and healthcare utilization of amyotrophic lateral sclerosis in China: A cohort study based on hospital data from 2015 to 2018.
    Song H; Liu JC; Cao ZP; Luo WJ; Chen JY
    Medicine (Baltimore); 2020 Nov; 99(47):e23258. PubMed ID: 33217848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria.
    Evers S; Goossens M; de Vet H; van Tulder M; Ament A
    Int J Technol Assess Health Care; 2005; 21(2):240-5. PubMed ID: 15921065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review and quality assessment of economic evaluation studies of injury prevention.
    Polinder S; Segui-Gomez M; Toet H; Belt E; Sethi D; Racioppi F; van Beeck EF
    Accid Anal Prev; 2012 Mar; 45():211-21. PubMed ID: 22269503
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.